The company announced today that the U.S. Patent and Trademark Office issued it a new patent covering the use of its laser technologies for treating various conditions of the eye, including cataracts, glaucoma, and presbyopia. The patent significantly broadens the claims for the patent family and anticipates using complimentary technologies to streamline procedures to identify the rigidity of the eye to optimize treatment locations in presbyopia procedures, for example.
The latest patent grant is the tenth U.S. patent issued under the “Methods for Treating Eye Conditions” patent family. Three other patents have been issued internationally and six more are pending worldwide. BIOLASE now holds a total of 20 issued and 20 pending U.S. and international patents in seven patent families in the field of ophthalmology. The patents give the company and its OCCULASE subsidiary a wide range of potential applications and coverage in the field.
This new patent is important for the company and its innovative WaterLase technology. Marcia Van Valen, director of business development for BIOLASE, said the patent further leverages the firm’s technology and broadens the patent family “to allow the laser parameters and groupings of tissue treatment to compensate for correlation in the various layers in ocular tissue for treating eye conditions such as presbyopia, cataract and glaucoma.”
For additional information about BIOLASE and its laser technologies, please visit www.biolase.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
